Primary central precocious puberty in male

disease
On this page

Summary

Primary central precocious puberty in male (MONDO:0958356) is a disease. A subtype of central precocious puberty in male — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameprimary central precocious puberty in male
Mondo IDMONDO:0958356
Orphanet650087
UMLSC5816763
MedGen1853130
GARD0027030
Is cancer (heuristic)no

Disease family

This is a subtype of central precocious puberty in male. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disordergonadal disorderprecocious pubertycentral precocious pubertycentral precocious puberty in maleprimary central precocious puberty in male

Related subtypes (1): secondary central precocious puberty in male

Subtypes (2): genetic central precocious puberty in male, non-genetic central precocious puberty in male

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.